| Quantity: | |
|---|---|
Clinically relevant – Mimics human RA pathogenesis: autoimmune polyarthritis, cartilage destruction, systemic inflammation.
Well-characterized endpoints – Clinical score, body weight, anti-collagen IgG, acute phase proteins (CRP, ALP), joint histopathology.
Reproducible induction – High incidence rate in susceptible NHP strains.
Translational value – Ideal for testing disease-modifying anti-rheumatic drugs (DMARDs), biologics, and targeted immunomodulators.
IND-ready data packages – Studies can be conducted in accordance with GLP principles.
Representative data from our NHP CIA model:
Collagen Induced Arthritis Model
• Efficacy testing of DMARDs, biologics (anti-TNF, anti-IL-6R), JAK inhibitors
• Target validation for autoimmune arthritis pathways
• Biomarker discovery (anti-collagen antibodies, acute phase proteins)
• Mechanism of action (MOA) studies
• IND-enabling toxicology and safety pharmacology studies
Parameter | Specification |
Species | Cynomolgus macaque (Macaca fascicularis) |
Induction method | Immunization with type II collagen (CII) in adjuvant (e.g., CFA/IFA) |
Study duration | 8–12 weeks post-immunization |
Key endpoints | Body weight, clinical arthritis score, anti-collagen IgG, CRP, ALP, joint histopathology, radiology (optional) |
Data package | Raw data, analysis reports, histology slides, bioinformatics (optional) |
Q: How is the CIA model induced in NHP?
A: By immunization with native type II collagen (CII) emulsified in complete Freund's adjuvant (CFA), followed by a booster injection. This triggers an autoimmune response against joint cartilage.
Q: What are the key similarities with human RA?
A: The model exhibits symmetric polyarthritis, synovial hyperplasia, pannus formation, cartilage erosion, and autoantibodies (anti-CII IgG), closely resembling human RA pathology.
Q: Can this model be used for IND-enabling studies?
A: Yes. Studies can be conducted in accordance with GLP principles for regulatory submissions (FDA, EMA).
Q: Do you offer customized study protocols (e.g., different adjuvants, dosing regimens)?
A: Absolutely. Our scientific team tailors immunization protocols, treatment schedules, and endpoint analyses to your specific drug candidate.